The current results demonstrated that BC had a CCKBR/p-ERK/p-P65-negative molecular subtype which corresponded to ER+, indicating that clinical trials targeting ERK1/2 could have been based on incorrect assumptions due to the complexity of ERK context. The gene discussed is CCKBR; the disease is breast cancer.